| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $200,000 | 1 | 50 |
Sells | $559,366 | 1 | 50 |
| Feehery William F | CHIEF EXECUTIVE OFFICER | 1 | $200,000 | 0 | $0 | $200,000 |
| Pedersen Leif E | PRESIDENT, CHIEF COMMERCAL OFF | 0 | $0 | 1 | $559,366 | $-559,366 |
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Over the last 12 months, insiders at Certara, Inc. have bought $200,000 and sold $559,366 worth of Certara, Inc. stock.
On average, over the past 5 years, insiders at Certara, Inc. have bought $340,486 and sold $430.54M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Feehery William F (CHIEF EXECUTIVE OFFICER) — $200,000.
The last purchase of 24,096 shares for transaction amount of $200,000 was made by Feehery William F (CHIEF EXECUTIVE OFFICER) on 2025‑11‑11.
| 2025-11-11 | Feehery William F | CHIEF EXECUTIVE OFFICER | 24,096.38 0.0143% | $8.30 | $200,000 | +3.15% | ||
| 2025-09-09 | Sale | Pedersen Leif E | PRESIDENT, CHIEF COMMERCAL OFF | 51,224 0.0318% | $10.92 | $559,366 | -15.74% | |
| 2024-10-07 | Sale | SMITH PATRICK F | PRESIDENT, DRUG DEV SOLUTIONS | 5,409 0.0035% | $11.03 | $59,661 | +1.13% | |
| 2024-09-09 | Sale | Pedersen Leif E | PRESIDENT, CHIEF COMMERCAL OFF | 51,224 0.0313% | $11.29 | $578,319 | -3.31% | |
| 2024-04-02 | Sale | SMITH PATRICK F | PRESIDENT, DRUG DEV SOLUTIONS | 14,427 0.009% | $16.85 | $243,161 | -27.26% | |
| 2024-04-01 | Sale | Traynor Richard M. | SVP AND GENERAL COUNSEL | 3,000 0.0019% | $18.00 | $54,000 | -31.22% | |
| 2024-03-04 | Sale | Traynor Richard M. | SVP AND GENERAL COUNSEL | 3,000 0.0018% | $18.28 | $54,840 | -29.42% | |
| 2024-02-20 | Sale | SMITH PATRICK F | PRESIDENT, DRUG DEV SOLUTIONS | 5,000 0.0032% | $18.00 | $90,000 | -21.29% | |
| 2024-02-12 | Sale | Traynor Richard M. | SVP AND GENERAL COUNSEL | 6,000 0.0038% | $18.00 | $108,000 | -23.76% | |
| 2023-12-26 | Sale | Traynor Richard M. | SVP AND GENERAL COUNSEL | 6,000 0.0037% | $18.00 | $108,000 | -14.51% | |
| 2023-09-11 | Sale | Pedersen Leif E | PRESIDENT, CHIEF COMMERCAL OFF | 51,224 0.0321% | $14.60 | $747,870 | +9.96% | |
| 2023-08-22 | BROSHY ERAN | director | 4,807 0.003% | $15.80 | $75,951 | +2.74% | ||
| 2023-08-21 | BROSHY ERAN | director | 193 0.0001% | $16.10 | $3,107 | -0.06% | ||
| 2023-06-05 | Sale | SMITH PATRICK F | PRESIDENT, INTEGRATED DRUG DEV | 19,104 0.0122% | $21.55 | $411,691 | -21.81% | |
| 2023-05-11 | Sale | Traynor Richard M. | SVP AND GENERAL COUNSEL | 5,000 0.0031% | $20.82 | $104,100 | -19.53% | |
| 2023-04-14 | Sale | Traynor Richard M. | SVP AND GENERAL COUNSEL | 5,000 0.0031% | $23.66 | $118,300 | -29.43% | |
| 2023-03-06 | Sale | Traynor Richard M. | SVP AND GENERAL COUNSEL | 10,000 0.0063% | $21.45 | $214,500 | -20.13% | |
| 2023-02-02 | Sale | Traynor Richard M. | SVP AND GENERAL COUNSEL | 15,000 0.0094% | $20.00 | $300,000 | -13.42% | |
| 2022-12-08 | Sale | EQT Avatar Parent L.P. | director | 29.95M 15.9478% | $15.00 | $449.32M | +0.56% | |
| 2022-11-22 | Sale | Pedersen Leif E | PRESIDENT, SOFTWARE | 51,223 0.0322% | $15.55 | $796,518 | +14.63% |
| Feehery William F | CHIEF EXECUTIVE OFFICER | 2360769 1.4822% | $16.67M | 1 | 15 | |
| Pedersen Leif E | PRESIDENT, CHIEF COMMERCAL OFF | 73979 0.0464% | $522,291.74 | 0 | 5 | |
| EQT Fund Management S.a r.l. | 29954521 18.807% | $211.48M | 0 | 2 | ||
| SLAINE MASON P | director | 660322 0.4146% | $4.66M | 0 | 10 | |
| Schemick Michael Andrew | CHIEF FINANCIAL OFFICER | 517870 0.3251% | $3.66M | 1 | 6 | +7.68% |
| CASHMAN JAMES E III | director | 438782 0.2755% | $3.1M | 1 | 2 | <0.0001% |
| Edge Justin | PRES., REGULATORY & ACCESS | 397090 0.2493% | $2.8M | 0 | 10 | |
| Rayner Craig R. | PRESIDENT, INTEGRATED DRUG DEV | 316010 0.1984% | $2.23M | 0 | 2 | |
| Aspbury Robert | PRESIDENT, SIMCYP | 278969 0.1752% | $1.97M | 0 | 6 | |
| Choe Jieun W. | CHIEF STRATEGY & MARKETING | 250491 0.1573% | $1.77M | 0 | 7 | |
| Traynor Richard M. | SVP AND GENERAL COUNSEL | 173524 0.1089% | $1.23M | 1 | 21 | <0.0001% |
| WALSH MATTHEW M | director | 167901 0.1054% | $1.19M | 1 | 1 | <0.0001% |
| SMITH PATRICK F | PRESIDENT, DRUG DEV SOLUTIONS | 50091 0.0314% | $353,642.46 | 0 | 8 | |
| McLean Stephen M. | 42000 0.0264% | $296,520.00 | 2 | 0 | <0.0001% | |
| BROSHY ERAN | director | 14360 0.009% | $101,381.60 | 2 | 0 | +1.34% |
| EQT Avatar Parent L.P. | director | 0 0% | $0 | 0 | 6 |
| Increased Positions | 127 | +41.78% | 19M | +13.49% |
| Decreased Positions | 136 | -44.74% | 14M | -9.46% |
| New Positions | 53 | New | 5M | New |
| Sold Out Positions | 38 | Sold Out | 2M | Sold Out |
| Total Postitions | 295 | -2.96% | 149M | +4.03% |
| Wasatch Advisors Lp | $152,061.00 | 10.94% | 17.4M | +4M | +28.56% | 2025-09-30 |
| Blackrock, Inc. | $121,556.00 | 8.75% | 13.91M | +571,575 | +4.29% | 2025-09-30 |
| Vanguard Group Inc | $108,441.00 | 7.8% | 12.41M | -27,221 | -0.22% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $72,999.00 | 5.25% | 8.35M | +499,523 | +6.36% | 2025-09-30 |
| Arrowmark Colorado Holdings Llc | $64,488.00 | 4.64% | 7.38M | -510,886 | -6.48% | 2025-09-30 |
| Deerfield Management Company, L.P. | $58,904.00 | 4.24% | 6.74M | +3M | +71.66% | 2025-09-30 |
| Geneva Capital Management Llc | $53,845.00 | 3.88% | 6.16M | +45,859 | +0.75% | 2025-09-30 |
| Teacher Retirement System Of Texas | $49,499.00 | 3.56% | 5.66M | -10,986 | -0.19% | 2025-09-30 |
| Ameriprise Financial Inc | $43,433.00 | 3.13% | 4.97M | -491,218 | -9% | 2025-09-30 |
| State Street Corp | $33,519.00 | 2.41% | 3.84M | +174,589 | +4.77% | 2025-09-30 |